US FDA grants Breakthrough Therapy Designation for combination immunotherapy in HCC treatment

Roche has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab)...

Sirtex prefers US$1.4 billion CDH-CGP bid to Varian’s acquisition offer

Sirtex has announced entering into a binding scheme implementation deed with CDH Genetech (CDH) and China Grand Pharmaceuticals and Healthcare Holdings Limited (CGP). It...

WCIO 2018 puts biopsy front and centre of the interventional oncology therapeutic armamentarium

The opening plenary at the World Conference on Interventional Oncology (WCIO; 7–10 June, Boston, USA) put biopsy, which is considered a mundane procedure by...

New data demonstrate clinical experience with LifePearl microspheres in over 300 hepatocellular carcinoma patients

Transarterial chemoembolization (TACE) using LifePearl (Terumo) drug-eluting embolic agents in the treatment of hepatocellular carcinoma has just been published.

Stephen B Solomon

Robert Morgan

Andrew Holden

Andrew Holden

(Visited 2,095 times, 1 visits today)